| Literature DB >> 34762062 |
Vikas Bansal1, Janice R Turek2, Aysun Tekin3, Shuchita Singh3, Neha Deo3, Mayank Sharma3, Marija Bogojevic1, Shahraz Qamar3, Romil Singh3, Vishakha Kumar4, Rahul Kashyap3.
Abstract
BACKGROUND: The rapid emergence of the COVID-19 pandemic globally collapsed health care organizations worldwide. Incomplete knowledge of best practices, progression of disease, and its impact could result in fallible care. Data on symptoms and advancement of the SARS-CoV-2 virus leading to critical care admission have not been captured or communicated well between international organizations experiencing the same impact from the virus. This led to the expedited need for establishing international communication and data collection on the critical care patients admitted with COVID-19.Entities:
Keywords: COVID-19; critical care; global; program management; registry
Year: 2022 PMID: 34762062 PMCID: PMC8929407 DOI: 10.2196/27921
Source DB: PubMed Journal: JMIR Res Protoc ISSN: 1929-0748
Figure 1VIRUS Global Pandemic Registry Team Organizations. AJW: Allan J Walkey. AT: Aysun Tekin. BU: Boston University. CM: Colleen McNamara. CS: Christopher R Sheldrick. GM: Gregory Martin. JT: Janice Turek. KB: Karen Boman. KG: Katja Gist. LR: Lynn Retford. MB: Marija Bogojevic. MC: Mayo Clinic. MG: Michael Garcia. MR: Mary Reidy. MS: Mayank Sharma. ND: Neha Deo. OG: Ognjen Gajic. PS: Phillip Schulte. RK: Rahul Kashyap. SHS: Smith Heavner. SJ: Shelsey Johnson. ST: Sandeep Tripathi. UB: Utpal Bhalala. VB: Vikas Bansal. VK: Vishakha Kumar.
Scope description of the VIRUSa registry.
| Scope | Description |
| In scope description and vision |
Scope: Hospitalized patients with COVID-19 who have positivity in PCR (or other SARS-CoV-2) test or test result pending or only observational clinical data. Vision: Real-time COVID-19 registry of current intensive care unit and hospital care patterns to allow evaluation of safety and observational effectiveness of COVID-19 practices. |
| Out of scope description |
Non-COVID-19–related admissions, COVID outpatients, any intervention, any biospecimen collection. |
aVIRUS: Viral Infection and Respiratory Illness Universal Study.
Figure 2Workflow of the VIRUS: COVID-19 International registry. DAG: data access group, PI: program investigator, PM: program manager.
Figure 3The one-year (April 2020-April 2021) trend of patient enrollment in VIRUS Registry.
Specifics of collected clinical data.
| Data groups | Details |
| Baseline characteristics |
Demographic characteristics Symptoms and history Comorbidities and premedications COVID-19 manifestations Microbiological test details |
| Daily follow-up |
Imaging results Respiratory support details Medications and other interventions Employment of best care practices |
| Outcome |
Requirement of oxygenation methods Complications during the follow-up period Hospital and intensive care unit length of stay In-hospital mortality 28-day mortality |
| Enhanced data point |
Daily vital signs Comprehensive physical examination findings Detailed laboratory results Sequential Organ Failure Assessment (SOFA) and Pediatric Logistic Organ Dysfunction (PELOD) scores |
| Full data |
Acute Physiological Assessment and Chronic Health Evaluation (APACHE) II score Electrocardiogram and echocardiography findings and deidentified image upload |
| Data regarding co-venting patients |
Demographics of both patients Detailed ventilator setting information Outcome of both patients |
| Pediatric-specific data |
Functional Status Score (FSS) and Pediatric Risk of Mortality (PRISM) scores |
Project management significance: structure of the weekly meeting sessions.
| Step/update | Specifics of the VIRUSa Registry weekly follow-up | Significance to project management |
| Automation update |
Data automation unit contributes with advancements in automated data collection. They also offer assistance and collaboration opportunities to participating institutions that are interested in automation. |
Although there have been substantial developments in electronic health record–based automated data collection, there is still room for improvement. Not all sites may have the means for developing a feasible automation system all by themselves. Thus, the collaboration of sites under the supervision of a professional team helps individual sites to establish a system that would make reliable automated data collection possible. |
| Adult VIRUS registry data update |
The project principal investigator brings the researchers up to date about the collected data. The study coordinating team provides comprehensive information about the updates in the standard operating procedure. They also indicate inconsistent and missing data points and share tips about improving the quality of collected data. |
Acknowledgment of achievements, both for the whole project and for each site, increases the motivation and collaboration of the centers. Detailed explanations of standard operating procedure amendments and their purpose help in attracting the attention of the collaborators to the updates and facilitate their compliance with the new or changed procedures. Providing guidance about how to improve data quality and offering partnership increase the efficiency of teamwork. |
| Ancillary study updates |
The project management team provides insight into the ancillary study proposal submission and the approval process. They extend guidance regarding approved ancillary study proposals. |
Being transparent in the ancillary proposal evaluation process helps with the building of trust within the study team. Offering guidance as necessary increases efficiency and strengthens teamwork. |
| Pediatric update |
The VIRUS: COVID-19 Registry Pediatric Team provides detailed information regarding the current status of pediatric data. They highlight pediatrics-specific data points. |
Providing pediatric-specific data during the general meeting strengthens the harmony between adult and pediatric sites. |
| Question and answer sessions |
More than half of weekly meetings is reserved for the question and answer session. The participants get an opportunity to inquire about any unclear points, and receive explanations directly from the study principal investigator. Fruitful discussions take place between the study coordinating team and participating researchers. |
The chance to have a personal discussion with the primary study team allows any issues to be clarified promptly. Additionally, because all investigators are a part of the conversation, it helps them to address the same situations quickly as they encounter them. During these conversations the primary study team has the opportunity to get direct feedback from other investigators, which leads to adjustments of the project according to the needs of the researchers. |
aVIRUS: Viral Infection and Respiratory Illness Universal Study.
Figure 4Active sites for the VIRUS: COVID-19 registry with the executive regional Leads.